A Comparative Safety and Pharmacokinetic Study of JHL1922 and Pulmozyme® in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 26, 2018

Primary Completion Date

June 22, 2018

Study Completion Date

May 21, 2019

Conditions

Healthy Subjects

Interventions

BIOLOGICAL

JHL1922

Single doses of JHL1922 2.5 mg and then 10 mg per eRapid nebulizer

BIOLOGICAL

dornase alfa

Single doses of Pulmozyme® 2.5 mg and then 10 mg per eRapid nebulizer

Trial Locations (1)

JHL Biotech Investigational Site, Groningen